Purple Biotech Ltd. Banner Image

Purple Biotech Ltd.

  • Ticker PPBT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Purple Biotech Ltd. Logo Image
  • 11-50 Employees
  • Based in Rehovot, Israel
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219, CM24 and IM1240. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. In a Phase 1/2 study of NT219, the Company is currently advancingMore it in a dose escalation as a monotherapy treatment of solid tumors, and in a dose escalation in combination with cetuximab for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) or colorectal adenocarcinoma (CRC). These studies will be followed by an expansion phase of NT219 at its recommended Phase 2 level in combination with cetuximab in patients with recurrent and metastatic SCCHN. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways.
4.8 / 5.0 (80)

Purple Biotech Ltd. reports have an aggregate usefulness score of 4.8 based on 80 reviews.

Purple Biotech Ltd.

Most Recent Annual Report

Purple Biotech Ltd.
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Purple Biotech Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!